Option Chain

Arrowhead Pharmaceuticals Inc

ARWRNASDAQ · USD

58.16USD+0.70 (+1.22%)

229

Arrowhead Pharmaceuticals Inc (ARWR) Option Chain

Arrowhead Pharmaceuticals Inc trades at $58.16, up 1.22%, with an IV Rank of 55.95%. This is average versus the past year, and the company carries a market cap of $8,116M in the Biotechnology industry. On the Nov 20, 2026 chain, the at the money $57.50 strike shows calls at $2.70 / $5.30 and puts at $1.30 / $3.40, both carrying about $2.85 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $60.00 calls, at 182 contracts, and the $57.50 puts, at 9, as of Nov 5, 2026.

Tracking the ARWR option chain helps you see every strike and expiry on Arrowhead Pharmaceuticals Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of ARWR options activity at a glance. Use our scanner to monitor the ARWR option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For ARWR stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where ARWR options are being actively traded, and where they are not.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma.

CALLs									PUTs
Prob. OTM %	Open Interest	Volume	Extrinsic Value	Intrinsic Value	Bid	Ask	Strike	Moneyness %	Bid	Ask	Intrinsic Value	Extrinsic Value	Volume	Open Interest	Prob. OTM %
26.33	0	0	0.49	5.66	4.10	8.20	52.50	-8.63	0.35	1.80	0.00	1.08	0	186	73.67
39.00	4	0	1.42	3.16	2.65	6.50	55.00	-4.28	0.75	3.70	0.00	2.23	0	85	61.00
52.34	237	0	3.34	0.66	2.70	5.30	57.50	+0.07	1.30	3.40	0.00	2.35	9	193	47.66
64.89	648	182	2.23	0.00	1.65	2.80	60.00	+4.42	2.60	6.70	1.84	2.81	0	1,715	35.11
75.58	1,589	26	2.05	0.00	1.40	2.70	62.50	+8.77	4.40	6.90	4.34	1.31	2	1,033	24.42

As of Nov 5, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

IndustryBiotechnology
SectorHealthcare
IV Rank55.95% Moderate
Market cap (M$)8,116
52 weeks high-39.83%
52 weeks low55.05%
Analyst recommendationStrong Buy
1.12
Target price$107.92
85.56% above the current stock price
Dividend—
Payout ratio—
Earnings date2026-11-12
P/E—
Future P/E—
EPS (ttm)-2.24
EPS growth next 5 years—

As of Nov 5, 2026

Browse all Option Chain tickers